Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy
Dan Sun, Xingjia Wang, He Wang, Zhiyi Shen, Xiangxu Meng, Yabin Zhou · 2026
Read Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy by Dan Sun, Xingjia Wang, He Wang, Zhiyi Shen, Xiangxu Meng, Yabin Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594805.txt.
Description
Dan Sun and co-authors review hormone talk in a 2026 paper on heart failure. When heart, kidney, and metabolic problems combine, the failing heart reflects stress signals from the whole body, not just the heart itself. The review centers on one axis: a bone hormone, FGF23, and its partner protein, Klotho.
Human studies link high FGF23 and altered Klotho to worse heart traits, and lab work makes the link plausible through growth and scarring of heart muscle. Direct causation in humans is not proven, the authors stress. Insulin resistance, fat tissue faults, anemia, and gut products all color the reading. Standard metabolic therapies are reviewed for their proven effects, not as proof of the axis theory.
Catalog record
| CREATOR | Dan Sun, Xingjia Wang, He Wang, Zhiyi Shen, Xiangxu Meng, Yabin Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 114 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |